TABLE 2.
The chi‐square test analysis of the connection between inflammation index and clinicopathological features.
| Characteristics | Intestinal type | Diffuse type and Mixed type | ||||
|---|---|---|---|---|---|---|
| SII≤529.24 (237) | SII>529.24 (141) | P value | PLR≤126.90 (225) | PLR>126.90 (153) | P value | |
| Sex | 0.040 | 0.559 | ||||
| Male | 184 (77.6) | 96 (68.1) | 165 (73.3) | 108 (70.6) | ||
| Female | 53 (22.4) | 45 (31.9) | 60 (26.7) | 45 (29.4) | ||
| Age (years) | 0.229 | 0.031 | ||||
| ≤60 | 146 (61.6) | 78 (55.3) | 151 (67.1) | 86 (56.2) | ||
| >60 | 91 (38.4) | 63 (44.7) | 74 (32.9) | 67 (43.8) | ||
| BMI | 0.007 | 0.205 | ||||
| ≤22.59 | 104 (43.9) | 82 (58.2) | 116 (51.6) | 89 (58.2) | ||
| >22.59 | 133 (56.1) | 59 (41.8) | 109 (48.4) | 64 (41.8) | ||
| NLR | <0.001 | <0.001 | ||||
| ≤1.99 | 203 (85.7) | 21 (14.9) | 164 (72.9) | 56 (36.6) | ||
| >1.99 | 34 (14.3) | 120 (85.1) | 61 (27.1) | 97 (63.4) | ||
| PLR | <0.001 | ‐ | ‐ | ‐ | ||
| ≤126.90 | 195 (82.3) | 27 (19.1) | ||||
| >126.90 | 42 (17.7) | 114 (80.9) | ||||
| SII | ‐ | ‐ | ‐ | <0.001 | ||
| ≤529.24 | 191 (84.9) | 60 (39.2) | ||||
| >529.24 | 34 (15.1) | 93 (60.8) | ||||
| CEA | 0.017 | 0.345 | ||||
| ≤5 ng/ml | 207 (87.3) | 110 (78.0) | 200 (88.9) | 131 (85.6) | ||
| >5 ng/ml | 30 (12.7) | 31 (22.0) | 25 (11.1) | 22 (14.4) | ||
| CA19‐9 | 0.071 | 0.028 | ||||
| ≤37 U/ml | 205 (86.5) | 112 (79.4) | 205 (91.1) | 128 (83.7) | ||
| >37 U/ml | 32 (13.5) | 29 (20.6) | 20 (8.9) | 25 (16.3) | ||
| CA72‐4 | 0.699 | 0.075 | ||||
| ≤15.520 U/ml | 214 (90.3) | 129 (91.5) | 201 (89.3) | 127 (83.0) | ||
| >15.520 U/ml | 23 (9.7) | 12 (8.5) | 24 (10.7) | 26 (17.0) | ||
| Borrmann type | <0.001 | 0.080 | ||||
| 0–2 | 130 (54.9) | 35 (24.8) | 98 (43.6) | 55 (35.9) | ||
| 3 | 90 (38.0) | 91 (64.5) | 105 (46.7) | 72 (47.1) | ||
| 4 | 17 (7.2) | 15 (10.6) | 22 (9.8) | 26 (17.0) | ||
| Tumor diameter (mm) | <0.001 | <0.001 | ||||
| ≤50 | 171 (72.2) | 61 (43.3) | 162 (72.0) | 75 (49.0) | ||
| >50 | 66 (27.8) | 80 (56.7) | 63 (28.0) | 78 (51.0) | ||
| Tumor location | 0.061 | 0.008 | ||||
| Middle and Upper third | 39 (16.5) | 32 (22.7) | 56 (24.9) | 29 (19.0) | ||
| Lower third | 178 (75.1) | 90 (63.8) | 150 (66.7) | 95 (62.1) | ||
| Entire stomach | 20 (8.4) | 19 (13.5) | 19 (8.4) | 29 (19.0) | ||
| pTNM stage | <0.001 | <0.001 | ||||
| Ⅰ | 94 (39.7) | 18 (12.8) | 76 (33.8) | 24 (15.7) | ||
| Ⅱ | 82 (34.6) | 42 (29.8) | 73 (32.4) | 41 (26.8) | ||
| Ⅲ | 61 (25.7) | 81 (57.4) | 76 (33.8) | 88 (57.5) | ||
| Tumor infiltration pattern (INF) | 0.761 | 0.966 | ||||
| INFa | 121 (51.1) | 73 (51.8) | 43 (19.1) | 28 (18.3) | ||
| INFb | 83 (35.0) | 52 (36.9) | 58 (25.8) | 41 (26.8) | ||
| INFc | 33 (13.9) | 16 (11.3) | 124 (55.1) | 84 (54.9) | ||
| Vascular infiltration | 0.029 | 0.008 | ||||
| No | 161 (67.9) | 80 (56.7) | 159 (70.7) | 88 (57.5) | ||
| Yes | 76 (32.1) | 61 (43.3) | 66 (29.3) | 65 (42.5) | ||
| Nerve infiltration | 0.022 | 0.186 | ||||
| No | 133 (56.1) | 62 (44.0) | 120 (53.3) | 71 (46.4) | ||
| Yes | 104 (43.9) | 79 (56.0) | 105 (46.7) | 82 (53.6) | ||
BMI: body mass index, NLR: neutrophil–lymphocyte ratio, PLR: platelet–lymphocyte ratio, SII: systemic immune‐inflammation index, CEA: carcinoembryonic antigen, CA19‐9: carbohydrate antigen 19–9, CA72‐4: carbohydrate antigen 72–4.
CEA, CA19‐9, and CA72‐4 were according to the tumor marker examination. Tumor location, tumor infiltration pattern, vascular infiltration, and nerve infiltration were according to the postoperative pathology report. INFa: expanding growth and a distinct border with the surrounding tissue, INFc: infiltrating growth and an indistinct border with the surrounding tissue, INFb: in‐between INFa and INFc. Statistically significant P values are in bold (p < 0.05).